Intelligent Bio Solutions (Nasdaq: INBS) advances 510(k) bid with key study
Rhea-AI Filing Summary
Intelligent Bio Solutions Inc. reported completion of an Interference Study for its Intelligent Fingerprinting Drug Screening System, a key element supporting an FDA 510(k) submission for U.S. market clearance to detect the opiate codeine.
The study, conducted with CenExel Clinical Research, Inc. under FDA guidance and ICH GCP standards, tested whether everyday substances such as hand creams, alcohol-based products, oils, dirt, and water affect test accuracy. Data analysis is underway, with independent verification via LC-MS/MS. The Interference Study forms part of a broader program including clinical cut-off, method comparison, precision, and penetration testing, and the company states it remains on track to submit its 510(k) package in calendar H2 2026 as it works toward entry into the multi-billion-dollar U.S. drug screening market.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
510(k) submission timing: calendar H2 2026
Test result time: under ten minutes
Target market size description: multi-billion-dollar U.S. drug screening market
3 metrics
510(k) submission timing
calendar H2 2026
Company states it remains on track to submit its FDA 510(k) package in this period
Test result time
under ten minutes
Intelligent Fingerprinting Drug Screening System provides results in under ten minutes
Target market size description
multi-billion-dollar U.S. drug screening market
Company describes planned entry into this market upon U.S. clearance
Key Terms
Interference Study, FDA 510(k) submission, ICH GCP (International Council for Harmonisation Good Clinical Practice), liquid chromatography-tandem mass spectrometry, +1 more
5 terms
Interference Study technical
"announced the completion of its Interference Study for the Intelligent Fingerprinting"
An interference study tests whether other substances or conditions prevent a medical test, drug measurement, or diagnostic device from working properly, like checking if a smartphone case blocks charging. Investors should care because interference problems can limit a product’s accuracy, regulatory approval, market acceptance, or lead to costly redesigns and lost sales, so clear results reduce risk and support commercial reliability.
FDA 510(k) submission regulatory
"The study supports the Company’s FDA 510(k) submission for U.S. market clearance"
An FDA 510(k) submission is a regulatory filing to show a new medical device is sufficiently similar to an already-approved device so it can be marketed in the U.S. without undergoing the most extensive premarket review. For investors, 510(k) clearance is a key milestone that reduces regulatory uncertainty and shortens time to sales—think of it as proving a new product is close enough to an established model to be sold without rebuilding trust from scratch.
ICH GCP (International Council for Harmonisation Good Clinical Practice) medical
"conducted with CenExel Clinical Research, Inc. and following FDA guidance and ICH GCP"
liquid chromatography-tandem mass spectrometry technical
"independent verification of results via liquid chromatography-tandem mass spectrometry"
Liquid chromatography-tandem mass spectrometry is a laboratory method that first separates a mixture of chemicals in liquid form and then identifies and measures each component by its weight, like first sorting beads by color and then weighing each pile. Investors care because it provides highly precise, trusted data used in drug development, safety testing and quality control; those results influence regulatory approvals, product reliability, timelines and financial risk for companies.
penetration testing technical
"program that included a clinical Cut-off Study, Method Comparison Study, precision testing, and penetration testing"
Penetration testing is a controlled security check where experts try to break into a company’s computer systems, networks or applications to find weaknesses before real attackers do. For investors it signals how well a company manages cyber risk, potential costs from breaches or compliance failures, and the firmness of operational defenses—think of it as hiring a professional to test all the locks and alarm systems so vulnerabilities can be fixed before they cause damage.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Intelligent Bio Solutions (INBS) announce in its August 3, 2026 8-K?
Intelligent Bio Solutions announced completion of its Interference Study for the Intelligent Fingerprinting Drug Screening System, a key component of its planned FDA 510(k) submission to support U.S. clearance for detecting the opiate codeine in workplace drug screening.
What is the purpose of the Interference Study for INBS’s fingerprinting system?
The Interference Study evaluates whether everyday substances on a fingertip, such as hand creams, alcohol-based products, oils, dirt, and water, affect the accuracy and reliability of the Intelligent Fingerprinting Drug Screening System’s codeine detection results under real-world field conditions.
How does the Interference Study support Intelligent Bio Solutions (INBS) FDA 510(k) submission?
The completed Interference Study forms part of a comprehensive evidence package for INBS’s planned FDA 510(k) submission, addressing accuracy, specificity, and reliability requirements for codeine detection and complementing clinical cut-off, method comparison, precision, and penetration testing data.
When does Intelligent Bio Solutions (INBS) plan to submit its 510(k) package?
Intelligent Bio Solutions states it remains on track to submit its 510(k) package in calendar H2 2026, aligning the completed Interference Study and other supporting studies with its timeline for seeking U.S. market clearance for the Intelligent Fingerprinting Drug Screening System.
What independent methods are being used to verify INBS Interference Study results?
Study data are undergoing analysis with independent verification via liquid chromatography-tandem mass spectrometry (LC-MS/MS), providing a high-specificity laboratory benchmark to confirm the Intelligent Fingerprinting Drug Screening System’s performance in detecting codeine under various contamination conditions.
What market is Intelligent Bio Solutions (INBS) targeting with its fingerprint drug test?
Intelligent Bio Solutions aims to enter the multi-billion-dollar U.S. drug screening market with its Intelligent Fingerprinting Drug Screening System, offering rapid, non-invasive workplace testing that screens for recent drug use with sample collection in seconds and results in under ten minutes.